Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 5Genitourinary 3Sarcoma 1Head & Neck 1Gynecologic 1CNS 1Breast 1

Conditions

Urinary Bladder Neoplasms 2Renal Pelvis and Ureter Urothelial Carcinoma 1Acrocephalosyndactylia 1

Interventions

Docetaxel 229Radiotherapy 206Magnetic Resonance Spectroscopy 204Radiosurgery 176Gemcitabine 155pembrolizumab 151Nivolumab 147enzalutamide 140Prednisone 129Cisplatin 123Leuprolide 119Androgen Antagonists 117Abiraterone Acetate 114Sunitinib 106Specimen Handling 94Surveys and Questionnaires 91Goserelin 91bicalutamide 90Carboplatin 88Ipilimumab 82gallium 68 PSMA-11 80Blood Specimen Collection 78Everolimus 73apalutamide 72Radiation 71Standard of Care 68Biopsy 68acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 66Paclitaxel 64Cyclophosphamide 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × infigratinib × Genitourinary × Clear all
NCT02657486 2026-02-09

BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

Memorial Sloan Kettering Cancer Center

Phase NA Completed
4 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT04228042 2025-01-01

Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
15 enrolled 10 charts
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

NCT04972253 2022-08-10

(BLASST)-3

Dana-Farber Cancer Institute

Phase 1 Withdrawn
Genitourinary

Acrocephalosyndactylia, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡